Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erythropoietin added to cardioplegia during CABG
IRCT20191216045755N1Phase 3Completed
- Sponsor
- Iran University of Medical Sciences
- Start
- Sep 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of erythropoietin in coronary arteriosclerosis (2 arms), sponsored by Iran University of Medical Sciences. Primary endpoints: Duration of ICU admission, Total postoperative hospital stay and 4 more. Started Sep 2019; status: completed.
02
Drugs
erythropoietin
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on IRCT20191216045755N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20191216045755N1.